Logo Logo
Hilfe
Hilfe
Switch Language to English

Stengel, Helena; Vural, Atay; Brunder, Anna-Michelle; Heinius, Annika; Appeltshauser, Luise; Fiebig, Bianca; Giese, Florian; Dresel, Christian; Papagianni, Aikaterini; Birklein, Frank; Weis, Joachim; Huchtemann, Tessa; Schmidt, Christian; Koertvelyessy, Peter; Villmann, Carmen; Meinl, Edgar; Sommer, Claudia; Leypoldt, Frank und Doppler, Kathrin (2019): Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. In: Neurology-Neuroimmunology & Neuroinflammation, Bd. 6, Nr. 5, e603

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Objective To identify and characterize patients with autoantibodies against different neurofascin (NF) isoforms. Methods Screening of a large cohort of patient sera for anti-NF autoantibodies by ELISA and further characterization by cell-based assays, epitope mapping, and complement binding assays. Results Two different clinical phenotypes became apparent in this study: The well-known clinical picture of subacute-onset severe sensorimotor neuropathy with tremor that is known to be associated with IgG4 autoantibodies against the paranodal isoform NF-155 was found in 2 patients. The second phenotype with a dramatic course of disease with tetraplegia and almost locked-in syndrome was associated with IgG3 autoantibodies against nodal and paranodal isoforms of NF in 3 patients. The epitope against which these autoantibodies were directed in this second phenotype was the common Ig domain found in all 3 NF isoforms. In contrast, anti-NF-155 IgG4 were directed against the NF-155-specific Fn3Fn4 domain. The description of a second phenotype of anti-NF-associated neuropathy is in line with some case reports of similar patients that were published in the last year. Conclusions Our results indicate that anti-pan-NF-associated neuropathy differs from anti-NF-155-associated neuropathy, and epitope and subclass play a major role in the pathogenesis and severity of anti-NF-associated neuropathy and should be determined to correctly classify patients, also in respect to possible differences in therapeutic response.

Dokument bearbeiten Dokument bearbeiten